Andrew Goodwin, PhD - Founder and Editor
Dr. Goodwin created BiotechDueDiligence as an individual investor looking to organize his notes and research about various biotech companies. It turned out that this information and analysis was popular with other biotech investors, and as they say, the rest was history!
After ten years of academic biomedical research, including a postdoctoral fellowship and faculty appointment at the Johns Hopkins University School of Medicine, Andrew now serves as a Pharmacologist at the Food and Drug Administration (FDA). He is a graduate of The College of William and Mary and earned a PhD in Cellular and Molecular Medicine from Johns Hopkins. Andrew is an author of more than 10 book chapters and peer-reviewed journal articles, including publications in the Proceedings of the National Academy of Science (PNAS), Cancer Research, and Clinical Infectious Diseases. Dr. Goodwin's biomedical analysis and writing has also appeared via Chimera Research Group and SeekingAlpha.
Andrew lives in the Washington, DC area with his wife and two children. Interact with Andrew on Twitter @BioDueDiligence and connect on LinkedIn (please mention BDD).
Please read and understand the DISCLAIMER.
Recognition for Dr. Goodwin and BiotechDueDiligence
November 2016: Featured on Regulatory Affairs Professional Society list "Using Twitter as an intelligence tool: 85 accounts worth following"
September 2015: Included on the MIT Biotechnology Group's list of the "Best Biotech News Sources"
April 2015: Included on Timmerman Report's list of Who Should Biotech and Pharma Industry Pros Follow on Twitter.
August 2014: Included on Alexander Gaffney's updated lists of top RSS Feeds and Twitter follows for life sciences / regulatory professionals published by Regulatory Focus / RAPS.
August 2013: Included as one of Adam Feuerstein's (TheStreet.com) "16 Essential Biotech Twitter Follows"
July 2013: Included on Alexander Gaffney's Regulatory Intelligence lists of top RSS Feeds and Twitter accounts to follow published by Regulatory Focus / RAPS.
September 2012: Included on Luke Timmerman's list of "Who Should Life Science Pros Follow on Twitter?" published by Xconomy.
November 2012: Ranked #33 of the Top 50 industry Voices in Biotech" list as compiled by FierceBiotech and Appeering/PeerIn. Be sure to check out the rest of the list.
Links/Mentions: BiotechDueDiligence content and commentary has been cited or linked in a variety of news outlets, including those featured below.
BiotechDueDiligence Current Contributors
Sarie (follow her @23aloha) is the mastermind behind the popular new "Biotech Tweets of the Week" feature!
Chris is a veteran manager in the medical device industry, with experience in the genomics, in-vitro diagnostics, and biosurgical sealant sectors. Follow Chris on Twitter @ware_am_i for the latest news and analysis of the medical device industry.
Dr. Duncan Emerton (on Twitter @biosimilarz) is the go-to source for news, discussion and analysis of the world of biosimilars product development. Check out his dedicated Biosimilarz website. Here at BiotechDueDiligence, check out his podcasts and guest blog posts.
FInd the site helpful?
Please make a contribution